number of access : ?
number of downloads : ?
ID 114508
Author
Tomiyama, Hirofumi Tokyo Medical University
Miwa, Takashi Tokyo Medical University
Kan, Kenshi Tokyo Medical University
Kamiya, Haruo Japanese Red Cross Nagoya Daiichi Hospital
Nanasato, Mamoru Japanese Red Cross Nagoya Daini Hospital
Kitano, Tomoki National Hospital Organization Nagoya Medical Center
Sano, Hiroaki Nagoya Ekisaikai Hospital
Ohno, Jun Tsushima Municipal Hospital
Iida, Masato Mitsubishi Nagoya Hospital
Maemura, Koji Nagasaki University
Tanaka, Atsushi Saga University
Murohara, Toyoaki Nagoya University
Node, Koichi Saga University
Keywords
Arterial stiffness
Dipeptidyl peptidase 4 inhibitor
Glycemic control
Content Type
Journal Article
Description
Background: No conclusive evidence has been obtained yet on the significance of the effects of dipeptidyl peptidase-4 (DPP-4 inhibitor) treatment on the arterial stiffness in clinical settings. In addition, the effects of good glycemic control on the arterial stiffness have also not been clarified yet. As a sub-analysis of the PROLOGUE study, we examined the effect of a DPP-4 inhibitor (sitagliptin) on the 2-year progression of the arterial stiffness and also to determine the effect of good glycemic control on the rate of progression of the arterial stiffness.
Methods: In the PROLOGUE study, the study participants were either allocated to add-on sitagliptin treatment or to continued treatment with conventional anti-diabetic agents. Among the 463 participants of the PROLOGUE study, we succeeded in measuring the brachial-ankle pulse wave velocity (baPWV) at least two times during the 2-year study period in 96 subjects.
Results: The changes in the baPWV during the study period were similar between the both groups (i.e., with/without staglipitin), overall. On the other hand, when the study subjects were divided into two groups according to the glycemic control status during the study period {good glycemic control group (GC) = hemoglobin (Hb)A1c <7.0 at both 12 and 24 months after the treatment randomization; poor glycemic control group (PC) = HbA1c ≥7.0 at either 12 months, 24 months, or both}, the 2-year increase of the baPWV was marginally significantly larger in the PC group (144 ± 235 cm/s) as compared to that the GC group (−10 ± 282 cm/s) (p = 0.036).
Conclusion: While the present study could not confirm the beneficial effect of sitagliptin per se on the arterial stiffness, the results suggested that good glycemic control appears to be beneficial for delaying the annual progression of the arterial stiffness.
Journal Title
Cardiovascular Diabetology
ISSN
14752840
Publisher
Springer Nature|BioMed Central
Volume
15
Start Page
150
Published Date
2016-11-03
Rights
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Institute of Advanced Medical Sciences
Medical Sciences
University Hospital